6-imidazol-1-yl-2-(4-iodo-2-methoxy-pyridin-3-yl)-4-methyl-1H-benzimidazole | 468740-99-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 6-imidazol-1-yl-2-(4-iodo-2-methoxy-pyridin-3-yl)-4-methyl-1H-benzimidazole
• 英文别名: 6-imidazol-1-yl-2-(4-iodo-2-methoxypyridin-3-yl)-4-methyl-1H-benzimidazole
• CAS: 468740-99-0
• 化学式: C₁₇H₁₄IN₅O
• 分子量: 431.236
• InChiKey: MFCFIGKITSBBJL-UHFFFAOYSA-N

物化性质

• 沸点：
  650.8±65.0 °C(Predicted)
• 密度：
  1.76±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  68.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-imidazol-1-yl-2-(4-iodo-2-methoxy-pyridin-3-yl)-4-methyl-1H-benzimidazole 在 盐酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 (+/-)-4-[2-(3-chloro-4-propoxy-phenyl)-2-hydroxy-ethylamino]-3-(6-imidazol-1-yl-4-methyl-1H-benzimidazol-2-yl)-1H-pyridin-2-one
  参考文献：
  名称：

  Novel 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase

  摘要：

  A novel class of 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase is described. This report discusses the SAR of 4-(2-hydroxy-2-phenylethylamino)-substituted pyridones with improved IGF-1R potency. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.11.041
• 作为产物：
  描述：

  在 palladium on activated charcoal 硫酸 、 氢气 、 potassium carbonate 、 potassium nitrate 作用下， 以 甲醇 为溶剂， 生成 6-imidazol-1-yl-2-(4-iodo-2-methoxy-pyridin-3-yl)-4-methyl-1H-benzimidazole
  参考文献：
  名称：

  Discovery and initial SAR of 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-ones as inhibitors of insulin-like growth factor 1-receptor (IGF-1R)

  摘要：

  The discovery and synthesis of 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor I receptor (IGF-1R) are presented. Installing amine containing side chains at the 4-position of pyridone ring significantly improved the enzyme potency. SAR and biological activity of these compounds is presented. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.01.102

文献信息

• Novel tyrosine kinase inhibitors
  申请人：——

  公开号：US20040044203A1

  公开（公告）日：2004-03-04

  The present invention provides compounds of formula I 1 and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inhibiting tyrosine kinase enzymes.

  本发明提供了公式I1的化合物及其药用盐。公式I化合物抑制酪氨酸激酶酶，因此可用作抗癌剂。公式I化合物还可用于治疗其他可以通过抑制酪氨酸激酶酶来治疗的疾病。
• [EN] NOVEL TYROSINE KINASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE LA TYROSINE KINASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2002079192A1

  公开（公告）日：2002-10-10

  The present invention provides compounds of formula I[ ] and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inhibiting tyrosine kinase enzymes.

  本发明提供了I[ ]式化合物及其药学上可接受的盐。I式化合物抑制酪氨酸激酶酶，因此可用作抗癌剂。I式化合物也可用于治疗其他可以通过抑制酪氨酸激酶酶来治疗的疾病。
• Tyrosine kinase inhibitors
  申请人：Bristol-Myers Squibb Company

  公开号：US07223757B2

  公开（公告）日：2007-05-29

  The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inhibiting tyrosine kinase enzymes.

  本发明提供了公式I的化合物及其药学上可接受的盐。公式I的化合物抑制酪氨酸激酶酶，因此可用作抗癌剂。公式I的化合物还可用于治疗其他可以通过抑制酪氨酸激酶酶来治疗的疾病。
• EP1381598A4
  申请人：——

  公开号：EP1381598A4

  公开（公告）日：2008-03-19
• NOVEL TYROSINE KINASE INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP1381598A1

  公开（公告）日：2004-01-21